Compare Ross Stores, Inc. (ROST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs TG Therapeutics Inc — how do they compare? Ross Stores, Inc. trades at $222.07 (market cap $71.94B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Ross Stores, Inc. is far larger — about 8.8× TG Therapeutics Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and TG Therapeutics Inc for 16 Days on average.
| ROST | TGTX | |
|---|---|---|
Market Cap | $71.94B | $8.16B |
Volume | 2,002,519 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $59.06 |
52-Week Low | $147.71 | $26.94 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | $72.39B | $8.37B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $222.41, down 1.38% amid broader market weakness. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability metrics including 42.63% ROE and 10.85% net margin. Technical indicators signal bearish momentum with the price near key support at $221, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion initiatives and strong closeout supply positioning the company for growth.
ROST presents a compelling investment case with strong operational performance and analyst confidence, though near-term technical weakness and competitive pressures warrant caution. The 16% upside to consensus target offers potential reward, but investors should monitor execution of expansion plans and consumer spending trends given the bearish technical signals.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
